Loading
A phase 1/2 trial of XNW27011 in ovarian cancer and colorectal cancer, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. is a phase 1/2 interventional study registered as NCT06792435 by Astellas Pharma Global Development, Inc., with 240 participants planned, started 2023-07-27 and due to reach its primary completion in 2026-12-30. Interventions recorded: XNW27011, XNW27011. Conditions listed: Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/